Phil Pang M.D.

Dr. Pang serves as Chief Medical Officer for Vir, where he is responsible for overseeing the company's global clinical development portfolio. His career in industry has been dedicated to the development of novel therapies to address some of the world's most challenging infectious diseases. Since joining the company in 2016, Dr. Pang has advanced numerous compounds through early - mid- and late-stage clinical development including the company's lead SARS-CoV-2 candidate, VIR-7831, which moved into Phase 3 in October 2020.

Prior to joining Vir, Dr. Pang serves as Chief Medical Officer of Riboscience LLC, a Roche-spinoff developing small molecule antivirals. Previously, during his four-year tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrix team to the successful worldwide approval of the first one-pill, once-a-day hepatitis C treatment.

Dr. Pang received his bachelor's degree in biological sciences from Stanford University and holds a Ph.D in biochemistry from Columbia University. His dissertation focused on viral molecular motors. He obtained his M.D. from Columbia University Vagelos College of Physicians and Surgeons, and completed his fellowship in infectious diseases at Stanford University.